August 4, 2017
Faron Pharmaceuticals to continue the INTEREST study as planned after IDMC’s recommendation
Faron Pharmaceuticals said Friday that Independent Data Monitoring Committee (the IDMC) has recommended that the Interest trial for Traumakine should continue as planned with no changes, consistent with the previous four IDMC recommendations. Faron said it expects to recruit 300 patients during the fourth quarter of 2017.